Trichomonas Vaginalis: controversy questions

Authors

DOI:

https://doi.org/10.18370/2309-4117.2017.38.31-34

Keywords:

trichomoniasis, diagnostics, treatment

Abstract

Trichomoniasis is the most common non-viral infection in the sexually transmitted world and is caused by Trichomonas vaginalis, a single-celled parasite that belongs to the flagellate class. Trichomoniasis is not subject to reporting in many countries, and therefore, assessing the prevalence of infection in population screening is complicated.

According to the WHO, in 2008 there were 276.4 million cases, the global prevalence of Tr. vaginalis was 8.1% for women and 1.0% for men. The level of Tr. vaginalis differs greatly from the population, the country, the methods of identification of the pathogen. One of the important reasons for diagnosis and treatment of T. vaginalis is the increased risk of infection and transmission of HIV from 2.1 to 2.8 times when it is available.

Most women (85%) and men (77%) with Tr. vaginalis have no clinical symptoms. In one third of infected women, symptoms appear within 6 months. Among those who have clinical manifestations, they are nonspecific: the presence of vaginal discharge of varying intensity and density, dysuria, itching, irritation, aching pain in the lower abdomen. The available diagnosis for Tr. vaginalis ranges from basic microscopy to nucleic acid amplification assays. Women are recommended to take biological material from the posterior vaginal fornix, men – urine, ejaculate, secret prostate.

ML DILA proposes the definition of Tr. vaginalis by the gold standard method of InPouch, or the simultaneous determination of the most common 4 pathogens and 3 conditional pathogens by the method of “Screening of STIs”. Control of treatment effectiveness according to the CDC Sexually Transmitted Diseases Treatment Guidelines are recommended for all women within the first 3 months after treatment, regardless of whether they consider their sexual partners cured, which is associated with a high risk of reinfection.

Author Biography

О. А. Бурка, Bogomolets National Medical University scientific consultant of medical laboratory “DILA”

PhD, assistant at the Obstetrics and Gynaecology Department No. 1

References

  1. Van Der Pol, B. “Trichomonas vaginalis Infection: The most prevalent nonviral sexually transmitted infection receives the least public health attention.” Clin Infect Dis 44.1 (2007): 23–5.
  2. World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections (2008).
  3. Centers for Disease Control and Prevention. DPDx – Laboratory Identification of Parasitic Diseases of Public Health Concern. Available from: [https://www.cdc.gov/dpdx/index.html], last accessed Dec 20, 2017.
  4. Association of Public Health Laboratories. Advances in Laboratory Detection of Trichomonas Vaginalis (Updated) (2016).
  5. Miller, W.C., Swygard, H., Hobbs, M.M., et al. “The prevalence of trichomoniasis in young adults in the United States.” Sex Transm Dis 32.10 (2005): 593–8.
  6. Sutton, M., Sternberg, M., Koumans, E.H., et al. “The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004.” Clin Infect Dis 45.10 (2007):1319–26.
  7. Wangnapi, R.A., Soso, S., Unger, H.W., et al. “Prevalence and risk factors for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis infection in pregnant women in Papua New Guinea.” Sex Transm Infect 91.3 (2015): 194–200.
  8. Dewi J. de Waaij, Jan Henk Dubbink, Sander Ouburg, et al. “Prevalence of Trichomonas vaginalis infection and protozoan load in South African women: a cross-sectional study, 2017.” BMJ Open 7/10 (2017): e016959.
  9. Kissinger, P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues.” BMC Infect Dis 15 (2015): 307.
  10. Ministry of Health of Ukraine. Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care «Urogenital Trichomonas Infection», project (2017).
  11. Mavedzenge, S.N., van der Pol, B., Cheng, H., et al. “Epidemiological synergy of Trichomonas vaginalis and HIV in Zimbabwean and South African women.” Sex Transm Dis 37 (2010): 460–6.
  12. Kissinger, P. “Epidemiology and Treatment of Trichomoniasis.” Curr Infect Dis Rep 17.6 (2015): 484.
  13. Domeyka, M., et al. Manual on laboratory diagnosis of infections of the urogenital tract. Sankt-Petersburg. N-L Publishing House (2012): 288 p.
  14. Centers for Disease Control and Prevention. “STD Treatment Guidelines 2015.” MMWR 64.3 (2015).
  15. Sherrard, J., Ison, C., Moody, J., et al. “United Kingdom National Guideline on the Management of Trichomonas vaginalis 2014.” Int J STD AIDS 25.8 (2014): 541–9.

Downloads

Published

2017-12-28

How to Cite

Бурка, О. А., & Сідорова, І. В. (2017). Trichomonas Vaginalis: controversy questions. REPRODUCTIVE ENDOCRINOLOGY, (38), 31–34. https://doi.org/10.18370/2309-4117.2017.38.31-34

Issue

No. 38 (2017)

Section

Inflammatory diseases

License

Copyright (c) 2017 О. А. Бурка, І. В. Сідорова

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.